CardioRenal, a company specialised in improving treatment at home for patients with severe chronic kidney disease (CKD), has secured funds of EUR3.3 million (USD3.7 million) from business angels and longstanding company shareholders (the management) as part of a round of seed capital financing.
This funding will enable the company to pursue its plan to achieve clinical and regulatory approval in preparation for the CE marking of its integrated tool, which is expected in 2023. CardioRenal completed a clinical trial on the technology in October 2021. The results of this trial will be presented at the European Renal Association congress in Paris, France, in May.
